You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Rilpivirine

Showing 1 - 25 of 154
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV Trial (Dolutegravir/Rilpivirine FDC)

Not yet recruiting
  • HIV Infections
  • Dolutegravir/Rilpivirine FDC
  • (no location specified)
Jan 5, 2023

Healthy Trial in Lenexa, Salt Lake City, Groningen (RPV LA, CAB LA)

Recruiting
  • Healthy
  • RPV LA
  • CAB LA
  • Lenexa, Kansas
  • +2 more
Jan 17, 2023

Satisfaction of HIV-infected Patients Treated With

Not yet recruiting
  • HIV Infections
  • satisfaction survey
  • (no location specified)
Jan 16, 2023

Human Immunodeficiency Virus Type 1 Trial in Worldwide (Rilpivirine)

Recruiting
  • Human Immunodeficiency Virus Type 1
  • Rilpivirine
  • Brescia, Italy
  • +13 more
Jan 17, 2023

Long-acting Injectable Cabotegravir + Rilpivirine

Not yet recruiting
  • Patient Satisfaction
  • +3 more
    • Santiago, Region Metropolitana, Chile
      CICUC
    Apr 18, 2023

    HIV Trial in Glendale (Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir extended release suspension for injection

    Completed
    • HIV Infections
    • Cabotegravir Tablets
    • +3 more
    • Glendale, California
      GSK Investigational Site
    Feb 14, 2022

    HIV-1-infection Trial (Etonogestrel (ENG) Subdermal Implants)

    Not yet recruiting
    • HIV-1-infection
    • Etonogestrel (ENG) Subdermal Implants
    • (no location specified)
    Jul 19, 2022

    HIV Trial (rilpivirine/cabotegravir)

    Not yet recruiting
    • HIV
    • (no location specified)
    Sep 25, 2023

    HIV, Fatty Liver Disease Trial in Madrid (Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil

    Recruiting
    • HIV Infections
    • Fatty Liver Disease
    • Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day
    • +2 more
    • Madrid, Spain
    • +3 more
    Jun 13, 2023

    HIV Trial (DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA)

    Not yet recruiting
    • HIV Infections
    • (no location specified)
    Jun 13, 2023

    Human Immunodeficiency Virus Infections Trial in India (Rilpivirine 25 mg, Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC))

    Terminated
    • Human Immunodeficiency Virus Infections
    • Rilpivirine 25 mg
    • Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)
    • Bengaluru, India
    • +5 more
    Jun 23, 2022

    HIV-1-infection Trial (Cabotegravir/Rilpivirine, Antiretroviral)

    Recruiting
    • HIV-1-infection
    • Kisumu, Kenya
    • +6 more
    Feb 1, 2023

    Human Immunodeficiency Virus, Opioid Use Disorder Trial in Providence (Combined LAI Treatment: Cabenuva and Sublocade)

    Recruiting
    • Human Immunodeficiency Virus
    • Opioid Use Disorder
    • Combined LAI Treatment: Cabenuva and Sublocade
    • Providence, Rhode Island
      Rhode Island Hospital
    Aug 7, 2023

    HIV Trial (Rilpivirine)

    Withdrawn
    • HIV Infections
    • Rilpivirine
    • (no location specified)
    Oct 28, 2021

    HIV Trial in Boston (CAB-RPV LA, Standard treatment within an HIV clinic)

    Enrolling by invitation
    • HIV Infections
    • CAB-RPV LA
    • Standard treatment within an HIV clinic
    • Boston, Massachusetts
    • +1 more
    Feb 24, 2022

    HIV-1-infection, HIV, HIV I Infection Trial (CAB + RPV)

    Not yet recruiting
    • HIV-1-infection
    • +2 more
    • CAB + RPV
    • (no location specified)
    Nov 16, 2022

    HIV Trial in Worldwide (Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Long-Acting Injectable Cabotegravir (CAB LA))

    Recruiting
    • HIV Infections
    • Oral Cabotegravir (CAB)
    • +4 more
    • La Jolla, California
    • +30 more
    Feb 2, 2023

    Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir Injectable Suspension, Rilpivirine Injectable

    Completed
    • Human Immunodeficiency Virus Type 1 (HIV-1)
    • Cabotegravir Injectable Suspension
    • Rilpivirine Injectable Suspension
    • Bakersfield, California
    • +31 more
    May 31, 2023

    HIV-1-infection, Medication Adherence, Satisfaction, Patient Trial in Little Rock (Home visit delivery strategy)

    Recruiting
    • HIV-1-infection
    • +2 more
    • Home visit delivery strategy
    • Little Rock, Arkansas
      University of Arkansas for Medical Sciences
    Oct 20, 2022

    Study Using Real-world Data in Human Immunodeficiency Virus-1

    Recruiting
    • HIV Infections
    • Tuebingen, Baden-Wuerttemberg, Germany
    • +22 more
    Jan 12, 2023

    Effect on HIV Medications on EPC Cells

    Completed
    • AIDS
    • Washington, District of Columbia
      The GW Medical Faculty Associates
    Mar 21, 2022

    HIV-1-infection Trial in Worldwide (Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable)

    Not yet recruiting
    • HIV-1-infection
    • Once daily CAB tablet + RPV tablet
    • Long acting CAB injectable + long acting RPV injectable
    • Atlanta, Georgia
    • +11 more
    Dec 13, 2022

    HIV-positive People, Treated With Long Acting Antiretroviral

    Active, not recruiting
    • HIV Infections
    • Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL
    • Milan, Italy
      Ospedale San Raffaele Scientific Institute
    Dec 15, 2022

    Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine -

    Active, not recruiting
    • Human Immunodeficiency Virus Type 1 (HIV-1)
    • Cabotegravir - Injectable Suspension (CAB LA)
    • Rilpivirine - Injectable Suspension (RPV LA)
    • Macon, Georgia
    • +29 more
    May 31, 2023

    HIV-1-infection Trial in Verona (HIV Treatment Satisfaction Questionnaire status)

    Completed
    • HIV-1-infection
    • HIV Treatment Satisfaction Questionnaire status
    • Verona, Italy
      AOUI Verona - UOC Malattie Infettive e Tropicali c/o Policlinico
    Jul 28, 2021